The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein

Immunology

Volumn 102, Issue 2, 2001, Pages 225-233

  Skinner, M A ^a,b   Prestidge, R ^a   Yuan, S ^a   Strabala, T J ^a   Tan, P L J ^a  

^a Genesis Research & Development Corporation Ltd   (New Zealand)

^b AGRESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FREUND ADJUVANT; HEAT SHOCK PROTEIN 65; IMMUNOLOGICAL ADJUVANT; MYCOBACTERIUM VACCINE; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CHAPERONINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNIZATION; MICE; MICE, INBRED C57BL; MYCOBACTERIUM; OVALBUMIN; SPLEEN; VACCINES, INACTIVATED;

EID: 0035106350     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01174.x     Document Type: Article

References (43)

1. Advances in vaccine adjuvants
2. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens
3. Le1F, a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
4. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response
5. Immunotherapy for tuberculosis. Investigative and practical aspects
6. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial
7. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172)
8. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection
9. Major histocompatibility complex class I-restricted cells are required for resistance to Mycobacterium tuberculosis infection
10. + cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis
11. Introduction of soluble protein into the class I pathway of antigen processing and presentation
12. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules
13. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
14. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
15. + cytotoxic T lymphocyte responses
16. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes
17. Induction of a CD8 + cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP)
18. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses
19. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins
20. + cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants
21. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
22. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant
23. + cytotoxic T-cell responses? A paradox revisited
24. Mycobacterium vaccae as a vaccine and therapeutic agent for tuberculosis: Role of natural killer cells
25. DNA vaccines
26. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway
27. Ribi adjuvants: Chemistry, biology and utility in vaccines for human veterinary medicine
28. Recombinant bacillus Calmette-Guerin as a potential vector for preventive HIV type 1 vaccines
29. + T cells
30. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
31. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity specific cytotoxic T lymphocytes
32. Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen
33. Cutting edge: Heat shock protein HSP60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells
34. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine
35. The IL-1 receptor/toll-like receptor suerfamily: Crucial receptors for inflammation and host defence
36. The CD14 ligands liparabinomannan and lipopolysaccharide differ in their requirement for toll-like receptors
37. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo
38. Induction of a Type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae
39. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae
40. Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series
41. Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172)
42. Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae